Skip to main content

Advertisement

SpringerLink
Log in

Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review

  • Immuno-oncology (RM Bukowski and JH Finke, Section Editors)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of the Review

The reintroduction of immune checkpoint inhibitors (ICIs) after disease progression (rechallenge) or immune-related adverse events (irAEs) recovering (resumption) raises questions in terms of efficacy and safety.

Recent Findings

Here, we reviewed literature data about ICIs rechallenge/resumption in cancer patients along with their clinical characteristics to explore those factors associated with better outcomes.

Summary

Heterogenous results were pointed out across rechallenge studies with an overall response rate between 0 and 54%, and a progression free survival ranged from 1.5 to 12.9 months and an overall survival between 6.5 and 23.8 months. Better outcomes have been recorded in patients with good ECOG PS, longer duration of initial ICI, discontinuation reason of initial ICI other than progression, and those who received ICI sequence other than the switch between anti-PD1 and anti-PDL1. Studies about ICI resumption highlighted that certain types of irAEs were more likely to relapse at retreatment. These results suggest that ICI rechallenge/resumption can be an interesting strategy for selected patients.

Graphical abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Joyce JA., Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Vol. 348, Science. American Association for the Advancement of Science; 2015. p. 69–74.

  2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Vol. 12, Nature Reviews Cancer. 2012. p. 252–64.

  3. Vaddepally RK, Kharel P, Pandey R, Garje R, Chandra AB. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Vol. 12, Cancers. MDPI AG; 2020.

  4. Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Vol. 20, Nature Immunology. Nature Publishing Group; 2019. p. 1425–34.

  5. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Vol. 19, Nature Reviews Cancer. Nature Publishing Group; 2019. p. 133–50.

  6. Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Vol. 37, Cancer Cell. Cell Press; 2020. p. 443–55.

  7. Lebbé C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, et al. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol. 2014;25(11):2277–84.

    Article  Google Scholar 

  8. •• Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–51. This post-hoc analysis explored the rechallenge strategy into a subgroup of melanoma patients who progressed after a first line of pembrolizumab with the Keynote-006 trial.

    Article  CAS  Google Scholar 

  9. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–18.

    Article  CAS  Google Scholar 

  10. Chiarion-Sileni V, Pigozzo J, Ascierto PA, Simeone E, Maio M, Calabrò L, et al. Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. Br J Cancer. 2014;110(7):1721–6.

    Article  CAS  Google Scholar 

  11. Shreders A, Joseph R, Peng C, Ye F, Zhao S, Puzanov I, et al. Prolonged benefit from ipilimumab correlates with improved outcomes from subsequent pembrolizumab. Vol. 4, Cancer Immunology Research. American Association for Cancer Research Inc.; 2016. p. 569–73.

  12. • Warner AB, Palmer JS, Shoushtari AN, Goldman DA, Panageas KS, Hayes SA, et al. Long-Term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade. 2020. Retrospective study on 78 patients evaluating clinical predictors of response to anti-PD1 rechallenge in melanoma patients.

  13. Formozo AA, Gomes JR, Schmerling RA, Buzaid AC. Retrospective analysis of rechallenge with Ipilimumab in patients with metastatic melanoma. Journal of Skin Cancer. 2021;2021.

  14. Asher N, Israeli-Weller N, Shapira-Frommer R, Ben-Betzalel G, Schachter J, Meirson T, et al. Immunotherapy discontinuation in metastatic melanoma: lessons from real-life clinical experience. Cancers. 2021 Jun 2;13(12).

  15. Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejberg L, et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol. 2019;30(7):1154–61.

    Article  CAS  Google Scholar 

  16. Klee G, Kurzhals J, Hagelstein V, Zillikens D, Recke A, Langan EA, et al. Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure. Melanoma Research. 2021;464–71.

  17. Aya F, Gaba L, Victoria I, Fernández-Martínez A, Tosca M, Prat A, et al. Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma. Future Oncol. 2016;12(23):2683–8.

    Article  CAS  Google Scholar 

  18. Kirchberger MC, Hauschild A, Schuler G, Heinzerling L. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma. Vol. 65, European Journal of Cancer. Elsevier Ltd; 2016. p. 182–4.

  19. Blasig H, Bender C, Hassel JC, Eigentler TK, Sachse MM, Hiernickel J, et al. Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma. Melanoma Res. 2017;27(4):321–5.

    Article  CAS  Google Scholar 

  20. Nomura M, Otsuka A, Kondo T, Nagai H, Nonomura Y, Kaku Y, et al. Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab. Cancer Chemother Pharmacol. 2017;80(5):999–1004.

    Article  CAS  Google Scholar 

  21. Katayama Y, Shimamoto T, Yamada T, Takeda T, Yamada T, Shiotsu S, et al. Retrospective efficacy analysis of immune checkpoint inhibitor rechallenge in patients with non-small cell lung cancer. Journal of Clinical Medicine. 2020 Jan 1;9(1).

  22. Waterhouse DM, Garon ; Edward B, Chandler J, Mccleod M, Hussein M, Jotte R, et al. Continuous versus 1-year fixed-duration nivolumab in previously treated advanced non-small-cell lung cancer: CheckMate 153. J Clin Oncol [Internet]. 2020;38. Available from: https://doi.

  23. •• Herbst RS, Garon EB, Kim D-W, Chul Cho B, Perez-Gracia JL, Han J-Y, et al. Long-Term Outcomes and retreatment among patients with previously treated, programmed death-ligand 1-positive, advanced non-small-cell lung cancer in the KEYNOTE-010 study. J Clin Oncol. 2020;38:1580–90. This post-hoc analysis explored the rechallenge efficacy into a subgroup of NSCLC patients who progressed after a first line of pembrolizumab with the Keynote-010 trial.

    Article  CAS  Google Scholar 

  24. Furuya N, Nishino M, Wakuda K, Ikeda S, Sato T, Ushio R, et al. Real-world efficacy of atezolizumab in non-small cell lung cancer: a multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody. Thoracic Cancer. 2021;12(5):613–8.

    Article  CAS  Google Scholar 

  25. • Gobbini E, First F, Toffart AC, Pérol M, Assié J-B, Duruisseaux M, et al. Clinical lung cancer immune checkpoint inhibitors re-challenge efficacy in non-small-cell lung cancer patients-manuscript draft. Retrospective study on 144 patients evaluating clinical predictors of response to anti-PD1/PD-L1 rechallenge in NSCLC patients.

  26. Fujita K, Uchida N, Kanai O, Okamura M, Nakatani K, Mio T. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases. Cancer Chemother Pharmacol. 2018;81(6):1105–9.

    Article  CAS  Google Scholar 

  27. Fujita K, Uchida N, Yamamoto Y, Kanai O, Okamura M, Nakatani K, et al. Retreatment with anti-PD-L1 antibody in advanced non-small cell lung cancer previously treated with anti-PD-1 antibodies. Anticancer Res. 2019;39(7):3917–21.

    Article  CAS  Google Scholar 

  28. Fujita K, Yamamoto Y, Kanai O, Okamura M, Hashimoto M, Nakatani K, et al. Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody. Thoracic Cancer. 2020;11(1):15–8.

    Article  CAS  Google Scholar 

  29. Kitagawa S, Hakozaki T, Kitadai R, Hosomi Y. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: case series and literature review. Thoracic Cancer. 2020;11(7):1927–33.

    Article  CAS  Google Scholar 

  30. Watanabe H, Kubo T, Ninomiya K, Kudo K, Minami D, Murakami E, et al. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer. Jpn J Clin Oncol. 2019;49(8):762–5.

    Article  Google Scholar 

  31. Niki M, Nakaya A, Kurata T, Yoshioka H, Kaneda T, Kibata K, et al. Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer [Internet]. 2018. Available from: www.oncotarget.com

  32. Ravi P, Mantia C, Su C, Sorenson K, Elhag D, Rathi N, et al. Evaluation of the safety and efficacy of immunotherapy rechallenge in patients with renal cell carcinoma. JAMA Oncol. 2020;6(10):1606–10.

    Article  Google Scholar 

  33. Gul A, Stewart TF, Mantia CM, Shah NJ, Gatof ES, Long YP, et al. Salvage ipilimumab and nivolumab in patients with metastatic renal cell carcinoma after prior immune checkpoint inhibitors. J Clin Oncol. 2020;38(27):3088–94.

    Article  CAS  Google Scholar 

  34. Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087 [Internet]. 2019. Available from: http://ashpublications.org/blood/article-pdf/134/14/1144/1223052/bloodbld2019000324.pdf

  35. Fedorova L v, Lepik K v, Mikhailova NB, Kondakova E v, Zalyalov YR, Baykov V v, et al. Nivolumab discontinuation and retreatment in patients with relapsed or refractory Hodgkin lymphoma.

  36. •• Sheth S, Gao C, Mueller N, Angra N, Gupta A, Germa C, et al. Durvalumab activity in previously treated patients who stopped durvalumab without disease progression. Journal for ImmunoTherapy of Cancer. 2020 Aug 26;8(2). Prospective clinical trial evaluating rechallenge with durvalumab in different tumor types after progression on the same agent.

  37. Bernard-Tessier A, Baldini C, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, et al. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. Eur J Cancer. 2018;1(101):160–4.

    Article  Google Scholar 

  38. •• Larkin J, Minor D, Angelo SD’, Neyns B, Smylie M, Miller WH, et al. JOURNAL OF CLINICAL ONCOLOGY Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol [Internet]. 2017; 36:383–90. Prospective study (CheckMate 037) evaluating the efficacy of rechallenge with nivolumab in melanoma patients pretreated with ipilimumab plus nivolumab compared to chemotherapy.

  39. Nomura M, Otsuka A, Kondo T, Nagai H, Nonomura Y, Kaku Y, et al. Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab. Cancer Chemotherapy and Pharmacology [Internet]. 2017;80(5):999–1004. Available from: https://doi.org/10.1007/s00280-017-3444-0

  40. Katayama Y, Shimamoto T, Yamada T, Takeda T, Yamada T, Shiotsu S, et al. Retrospective efficacy analysis of immune checkpoint inhibitor rechallenge in patients with non-small cell lung cancer. J Clin Med. 2019;9(1):102.

    Article  Google Scholar 

  41. Fujita K, Uchida N, Kanai O, Okamura M, Nakatani K, Mio T. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases. Cancer Chemotherapy and Pharmacology [Internet]. 2018;81(6):1105–9. Available from: https://doi.org/10.1007/s00280-018-3585-9

  42. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.

    Article  CAS  Google Scholar 

  43. Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis. Vol. 5, JAMA Oncology. American Medical Association; 2019. p. 1195–204.

  44. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–33.

    Article  CAS  Google Scholar 

  45. Giaj Levra M, Cotté FE, Corre R, Calvet C, Gaudin AF, Penrod JR, et al. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer. 2020;1(140):99–106.

    Article  Google Scholar 

  46. Ravi P, Mantia C, Su C, Sorenson K, Elhag D, Rathi N, et al. Evaluation of the safety and efficacy of immunotherapy rechallenge in patients with renal cell carcinoma. JAMA Oncol. 2020;6(10):1606–10.

    Article  Google Scholar 

  47. Weber J, Gibney G, Kudchadkar R, Yu B, Cheng P, Martinez AJ, et al. Phase I/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab. Cancer Immunol Res. 2016;4(4):345–53.

    Article  CAS  Google Scholar 

  48. Buchbinder EI, Desai A. CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition. Vol. 39, American Journal of Clinical Oncology: Cancer Clinical Trials. Lippincott Williams and Wilkins; 2016. p. 98–106.

  49. Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL, Lawrence DP, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016;17(7):943–55.

    Article  CAS  Google Scholar 

  50. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–84.

    Article  CAS  Google Scholar 

  51. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Vol. 8, Nature Reviews Cancer. 2008. p. 425–37.

  52. Hannani D, Sistigu A, Kepp O, Galluzzi L, Kroemer G, et al. Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. The Cancer Journal & [Internet]. 17(5). Available from: www.journalppo.com351

  53. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Vol. 31, Annual Review of Immunology. 2013. p. 51–72.

  54. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Vol. 140, Cell. Elsevier B.V.; 2010. p. 798–804.

  55. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203(5):1259–71.

    Article  CAS  Google Scholar 

  56. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174(12):7516–23.

    Article  CAS  Google Scholar 

  57. Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Can Res. 2011;71(7):2488–96.

    Article  CAS  Google Scholar 

  58. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Investig. 2014;124(2):687–95.

    Article  CAS  Google Scholar 

  59. • Simonaggio A, Michot JM, Voisin AL, le Pavec J, Collins M, Lallart A, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncology. 2019 Sep 1;5(9):1310–7. Retrospective study on 40 patients evaluating clinical predictors of irAEs occurrence upon immunotherapy resumption in patients who experienced a grade ≥ 2 adverse events on previous immunotherapy regardless of tumor type.

  60. Delaunay M, Cadranel J, Lusque A, Meyer N, Gounaut V, Moro-Sibilot D, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. European Respiratory Journal. 2017 Aug 1;50(2).

  61. Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. The Lancet Haematology. 2019;6(1):e48-57.

    Article  Google Scholar 

  62. Isik B, Alexander MP, Manohar S, Vaughan L, Kottschade L, Markovic S, et al. Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events. Kidney International Reports. 2021;6(4):1022–31.

    Article  Google Scholar 

  63. Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6(6):865–71.

    Article  Google Scholar 

  64. Patrinely JR, McGuigan B, Chandra S, Fenton SE, Chowdhary A, Kennedy LB, et al. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. OncoImmunology. 2021;10(1).

  65. de Malet A, Antoni G, Collins M, Soularue E, Marthey L, Vaysse T, et al. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. Eur J Cancer. 2019;1(106):106–14.

    Article  Google Scholar 

  66. Wang H, Zhao Y, Zhang X, Si X, Song P, Xiao Y, et al. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: a single-institution retrospective study. Cancer Med. 2021;10(1):188–98.

    Article  CAS  Google Scholar 

  67. Nahar KJ, Rawson R v., Ahmed T, Tattersall S, Sandanayake N, Kiely CJ, et al. Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. Journal for ImmunoTherapy of Cancer. 2020 Nov 24;8(2).

  68. Abu-Sbeih H, Faisal ;, Ali S, Abdul ;, Naqash R, Owen DH, et al. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol [Internet]. 2019;37:2738–45. Available from: https://doi

  69. Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, et al. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥ 2 immune-related adverse events in patients with cancer. Journal for ImmunoTherapy of Cancer. 2020 Dec 21;8(2).

  70. Alaiwi SA, Xie W, Nassar AH, Dudani S, Martini D, Bakouny Z, et al. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 2020 Feb 16;8(1).

  71. Bhatlapenumarthi V, Patwari A, Harb AJ. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience. J Cancer Res Clin Oncol. 2021;147(9):2789–800.

    Article  CAS  Google Scholar 

  72. • Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunology Research. 2018 Sep 1;6(9):1093–9. Retrospective study conducted in NSCLC patients discontinuing the immunotherapy because of toxicity analyzing irAEs recurrence at immunotherapy resumption and clinical determinants for safety profile.

  73. Tsui, PharmD A, Edmondson, PharmD, BCOP L, Julius, PharmD J. An evaluation of the use of corticosteroids for the management of immune-mediated adverse events in cancer patients treated with immune checkpoint inhibitors. Journal of the Advanced Practitioner in Oncology. 2021 Mar 1;12(2).

  74. Kartolo A, Holstead R, Khalid S, Emack J, Hopman W, Baetz T. Safety of immunotherapy rechallenge after immune-related adverse events in patients with advanced cancer [Internet]. 2020. Available from: www.immunotherapy-journal.com

  75. Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018;29(1):250–5.

    Article  CAS  Google Scholar 

  76. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, et al. Title: Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab Downloaded from [Internet]. 2016. Available from: http://annonc.oxfordjournals.org/

  77. Albandar HJ, Fuqua J, Albandar JM, Safi S, Merrill SA, Ma PC. Immune-related adverse events (Irae) in cancer immune checkpoint inhibitors (ici) and survival outcomes correlation: to rechallenge or not? Cancers. 2021;13(5):1–15.

    Article  Google Scholar 

  78. Mouri A, Kaira K, Yamaguchi O, Shiono A, Miura Y, Hashimoto K, et al. Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer. Cancer Chemother Pharmacol. 2019;84(4):873–80.

    Article  CAS  Google Scholar 

  79. • Shah P, Punekar SR, Pavlick AC. Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma. Melanoma Research. 2021;242–8. Retrospective study conducted in melanoma patients discontinuing the immunotherapy because of toxicity analyzing irAEs recurrence at immunotherapy resumption and clinical determinants for safety profile.

Download references

Acknowledgements

We would like to thank Jordan Sacareau, Nicolas Ozan, and Bruno Schoentjes for the project about definition and support during the paper writing.

Funding

D.H. is supported by GEFLUC Dauphiné-Savoie, Ligue contre le Cancer Comité Isère, Université Grenoble Alpes IDEX Initiatives de Recherche Stratégiques, and Fondation du Souffle, Fonds de recherche en santé respiratoire (FdS-FRSR).

E.G. is supported by the ITMO INSERM.

Author information

Authors and Affiliations

  1. CHU Grenoble-Alpes, Biological and Pathological Institute, Avenue Maquis du Gresivaudan, 38700, La Tronche, France

    Caroline Plazy

  2. Univ. Grenoble Alpes, CNRS, Grenoble INP, CHU Grenoble Alpes, TIMC, UMR 5525, VetAgro Sup, 38000, Grenoble, France

    Caroline Plazy & Dalil Hannani

  3. Thoracic Oncology Unit, CHU Grenoble-Alpes, Avenue Maquis du Gresivaudan, 38700, La Tronche, France

    Elisa Gobbini

  4. Cancer Research Center of Lyon, CISTAR Research Team, 28 rue Laennec, 69008, Lyon, France

    Elisa Gobbini

Authors
  1. Caroline Plazy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dalil Hannani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elisa Gobbini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elisa Gobbini.

Ethics declarations

Conflict of Interest

Caroline Plazy declares that she has no conflict of interest. Dalil Hannani declares that he has no conflict of interest. Elisa Gobbini is the spouse of an employee of AstraZeneca, and has received speaker’s honoraria from Roche, Merck Sharp & Dohme, Bristol-Myers Squibb, Pfizer, and AstraZeneca.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical collection on Immuno-oncology

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 477 KB)

Appendix 1

Appendix 1

Search methods for systematic review on Pubmed database.

The extraction of all the publications was performed on Pubmed, using the following terms: « rechallenge», « retreatment», « re-administration» « reintroduction», « resumption» « discontinuation» followed by « immunotherapy», « immune checkpoint inhibitor», « nivolumab», « pembrolizumab», « ipilimumab» « atezolizumab», « durvalumab», « avelumab», « tremelimumab».

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Plazy, C., Hannani, D. & Gobbini, E. Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review. Curr Oncol Rep 24, 1095–1106 (2022). https://doi.org/10.1007/s11912-022-01241-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-022-01241-z

Keywords

Search

Navigation